Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cronos Group Q3 2026 Results: Net Income $13.8M, Down 46.8% YoY

Cronos Group reported a significant increase in net revenue to $63.5 million for Q3 2026, up from $36.3 million in the prior year period, driven by growth in cannabis sales. The company achieved an operating income of $9.0 million for the quarter, a substantial improvement from the operating loss of $0.5 million in Q3 2025, while maintaining a strong cash and short-term investment position of approximately $741 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue83.948.8
Gross profit32.318.3
Profit before tax18.727.0
Net income13.826.0
EPS (diluted, $ a share)$0.04$0.07

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-46.8%
Revenue, year on year+71.8%
Gross margin38.5%
Operating margin10.8%
Source

10-Q filed with the SEC, NASDAQ: CRON. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cronos Group Inc.: key numbers

Share price
$3.27Close, Nov 16
Market cap
$1.2B
Shares outstanding
366.47MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cronos Group Inc.

All →
7:32 AM ET 8-K
Financial Results

Cronos Group Financial Results

Cronos Group reported record Q3 2026 financial results, with net revenue increasing 75% year-over-year to $63.5 million. The company achieved record performance in Canada, Israel, and Germany, while maintaining a strong balance sheet and continuing its share repurchase program.

Term
Q3 2026

“Cronos organically achieved records across net revenue, gross profit, and Adjusted EBITDA for the second consecutive quarter, while at the same time reducing shares outstanding.”

Mike Gorenstein, Chairman, President and CEO

“Our strategic focus on the development and production of market-leading borderless products continues to pay off, reflected in another record quarter of results.”

Mike Gorenstein, Chairman, President and CEO
7:02 AM ET 8-K
M&A Deal

Cronos Group M&A Deal with CanAdelaar B.V.

Cronos Group completed the acquisition of CanAdelaar B.V., a licensed cannabis grower in the Dutch Controlled Cannabis Supply Chain Experiment, for a base purchase price of €57.5 million plus earnouts. The deal establishes Cronos' European platform in the Netherlands' adult-use cannabis pilot program, with the buyer deducting €12.5 million from the initial price to cover a potential environmental penalty.

Counterparty
CanAdelaar B.V.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.